3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Small Cell Lung Carcinoma
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Lymphoma, Large B-Cell, Diffuse
11
Lung Neoplasms
10
Burkitt Lymphoma
9
Leukemia, Myeloid, Acute
8
Lymphoma
7
Hodgkin Disease
6
Carcinoma, Non-Small-Cell Lung
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms
5
Multiple Myeloma
5
Lymphoma, Non-Hodgkin
5
Lymphoma, B-Cell
5
Sarcoma, Ewing
3
Sarcoma
3
Rhabdomyosarcoma
3
Rhabdoid Tumor
3
Retinoblastoma
3
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neuroblastoma
3
Neoplasms, Germ Cell and Embryonal
3
Myelodysplastic Syndromes
3
Medulloblastoma
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Leukemia
3
Immunoblastic Lymphadenopathy
3
Seminoma
2
Interventions
Cisplatin
10
pembrolizumab
8
Carboplatin
8
durvalumab
5
Pemetrexed
5
Paclitaxel
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
osimertinib
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Taxes
3
Gemcitabine
3
Bevacizumab
3
cabozantinib
2
atezolizumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Platinum
2
Nivolumab
2
Immunoglobulin G
2
Docetaxel
2
Disulfides
2
CP protocol
2
Biopsy
2
1,2-diaminocyclohexaneplatinum II citrate
2
tremelimumab
1
relatlimab
1
peposertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma
×
Etoposide
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled